NASDAQ:CYTR

LadRx (CYTR) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.09
$0.10
52-Week Range
N/A
Volume
4,000 shs
Average Volume
99,706 shs
Market Capitalization
$4.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYTR stock logo

About LadRx Stock (NASDAQ:CYTR)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

CYTR Stock News Headlines

LadRx (LADX) Earnings Dates & Reports
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
LadRx Corporation Announces OTCQB Ticker Change to LADX
CytRx Corporation Relaunches as LadRx Corporation
European Patent Office Awards CytRx Key Patent
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
See More Headlines
Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTR
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$4.14 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Stephen Snowdy
    Chief Executive Officer
  • John Y. Caloz
    Chief Financial Officer, Treasurer & Senior VP
  • Felix Kratz
    Vice President-Drug Discovery
  • Cristina Newman
    Secretary

This page (NASDAQ:CYTR) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners